Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital

Lucid Capital upgraded Tvardi Therapeutics (TVRD) to Buy from Neutral with a $6 price target The firm finds the stock undervalued at current levels. Lucid’s model suggests TTI-101 in hepatocellular carcinoma and TTI-109 could be worth $6 per share. Tvardi is currently trading near its cash value levels, the analyst tells investors in a research note. Lucid cites valuation and the potential for Tvardi’s assets to inflect the story with key readouts this year for the upgrade.